Abstract
Notwithstanding the progress recently made in immunology and virology, there is yet no effective, specific treatment for the common cold. Symptomatic treatment is minimally effective. An anecdotal report of rapid clearing of the common cold of recent onset after intranasal application of imiquimod in several subjects by one of the authors, made us test the hypothesis that this treatment works through the secretion of interferon by the nasal mucosa. We decided to do an animal study in primates (Indian Macaca Mulata): 5 treatment and 3 control animals were used. Imiquimod or placebo was massaged into the nares of the animals and periodic samples of post‐nasal fluid were taken and measurements for Interferon α (IFNα) and Tumor Necrosis Factor α (TNFα) were made by ELISA methods, and kinetic studies. IFNα mRNA was also isolated and analyzed by quantitative competitive RT‐PCR. The internal standard was constructed to be complementary to and compete with oligonucleotide primers and for amplification of target sequences. One intranasal application of imiquimod rapidly (1–4 h) induced high levels of mRNA for IFNα, and minimal levels in the control animals. Rapid induction of INFα, and proportional increase of TNFα sustained for 4 and 6 h respectively were noted. No adverse reactions to treatment were found in macaques during this short period of intranasal imiquimod usage (except in one macaque with a short period of lacrimation). No animal had cytotoxic effects when examined at 6 h, 12 h, 24 h or 48 h, except one animal, which had an episode of lacrimation for 6hr post treatment. Thus both safety and efficacy of short treatment with imiquimod is proven in this animal model. Proof of principle for intranasal treatment of the common cold with imiquimod is shown. We think that this work will encourage a number of double blind clinical trials to confirm the effectiveness of the intranasal treatment of the common cold with imiquimod.
Keywords: common cold, Imiquimod, interferon‐ α, intranasal antiviral treatment
References
- 1. Verdaguer N, Fita I, Reithmayer M, Moser R, Dieter B. X‐ray structure of a minor group human rhinovirus bound to a fragment of its cellular receptor protein. Nat Struct Mol Biol. 2004; 11: 429–34. [DOI] [PubMed] [Google Scholar]
- 2. Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Derm. 2002; 27: 571–7. [DOI] [PubMed] [Google Scholar]
- 3. Oster‐Schmidt C. Imiquimod: a new possibility for treatment‐resistant verrucae planae. Arch Dermatol. 2001; 137: 666–7. [PubMed] [Google Scholar]
- 4. Barba AR, Kapoor S, Berman B. An open label safety study of topical Imiquimod 5% cream in the treatment of Molluscum contagiosum in children. Dermatol Online J. 2001; 7: 20. [PubMed] [Google Scholar]
- 5. Marks R, Gebauer K, Schumack S, Amies M, Bryden J, Fox TL, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6‐week dose‐response trial. J Am Acad Dermatol. 2001; 44: 807–13. [DOI] [PubMed] [Google Scholar]
- 6. Schroeder TL, Senglemann RD. Squamous cell carcinoma in situ of the penis successfully treated with Imiquimod 5% cream. J Am Acad Dermatol. 2002; 46: 545–8. [DOI] [PubMed] [Google Scholar]
- 7. Smith KJ, Germain M, Skelton H. Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% Imiquimod and 5% 5‐fluorouracil therapy. Dermatol Surg. 2002; 27: 56–64. [DOI] [PubMed] [Google Scholar]
- 8. Stockfleth E, Meyer T, Benninghoff B, Christophers E. Successful treatment of actinic keratosis with Imiquimod cream 5%: a report of six cases. Br J Dermatol. 2001; 144: 1050–3. [DOI] [PubMed] [Google Scholar]
- 9. Agrawal S, Berth‐Jones J. Porokeratosis of Mibelli: successful treatment with 5% Imiquimod cream. Br J Dermatol. 2002; 146: 338–9. [DOI] [PubMed] [Google Scholar]
- 10. Harrison CJ, Jenski L, Voychehovski T, Bernstein DI. Modification of immunological responses and clinical disease during topical R‐837 treatment of genital HSV‐2 infection. Antiviral Res. 1998; 10: 209–23 [erratum appears in Antiviral Res. 1989; 11: 215]. [DOI] [PubMed] [Google Scholar]
- 11. Weeks CE, Reiter MJ. Antiviral/immunomodulator R‐837 induces α interferon in mice. J Invest Dermatol. 1989; 93: 584. [Google Scholar]
- 12. Gibson SJ, Elrod SV, Miller RL, Weeks CE. Oral R‐837 induces α interferon in cynomolgous monkeys. J Interferon Res. 1990; 10: S124–40. [Google Scholar]
- 13. Reiter MJ, Testerman TL, Miller RL, Weeks CE, Tomai MA. Cytokine induction in mice by the immunomodulator Imiquimod. J Leukoc Biol. 1994; 55: 234–40. [DOI] [PubMed] [Google Scholar]
- 14. Marsh M, Pelchen‐Matthews A. Endocytosis in viral replication. Traffic 2002; 1: 525–32. [DOI] [PubMed] [Google Scholar]
- 15. Haagmans B, Kuiken T, Martina BE, Fouchier RA, Rimmelzwaan GF, van Amerongen G, et al. 2004. Pegylated interferon‐a protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nature Med. 2004; 10: 290–303. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Mihm S, Frese M, Meier V, Weitzke‐Braun P, Scharf J‐G, Bartenschlager R, et al. Inteferon type I gene expression in chronic hepatitis. C Lab Invest. 2004; 84: 1148–59. [DOI] [PubMed] [Google Scholar]
- 17. Fouchier RAM, Bestebroer TM, Herfst S, van den Kemp L, Rimmelzwan GF, Osterhaus ADME. Detection of influenza viruses from different species by PCR amplification of conserved sequences in the matrix gene. J Clin Microbiol. 2000; 38: 4096–5001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. DeTulleo L, Kirchhausen T. The clathrin endocytic pathway in viral infection. EMBO J. 1998; 17: 4585–93. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Cherry S, Perrion N. Entry is a rate‐limiting step for viral infection in a Drosophila melanogastor model of pathogenesis. Nature Immun. 2003; 5: 81–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Dahl M. Imiquimod: case of early clinical experience in various conditions. J Am Acad Dermatol. 2002; 47: S205–8. [DOI] [PubMed] [Google Scholar]
- 21. Arrese Jorge E, Philippe Paquet, Nadine Claessens, Claudine Piérard‐Franchimont, Piérard Gérald E. Dermal dendritic cells in anogenital warty lesions unresponsive to an immune‐response modifier. J Cutan Patol. 2001; 28: 131–4. [DOI] [PubMed] [Google Scholar]